EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Retrospective Cohort Study Evaluating the Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and Tyrosine Kinase Inhibitor-Associated Toxicity in Advanced Renal Cell Carcinoma

Theodore Joseph Miller, Junjia Zhu, Megan Wheelden, Ashok Maddukuri, Michael Elias, Naman Trivedi, Monika Joshi

Journal of Urologic Oncology · 31.07.2026 · 24 (2) · 162-171

DOI: 10.22465/juo.265200060003 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Urologic Oncology, erschienen am 31.07.2026. Verfasst von Theodore Joseph Miller und 6 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Tyrosine kinase inhibitors (TKIs) used to treat advanced renal cell carcinoma are associated with clinically significant toxicities, including hypertension and acute kidney injury. Because angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEis/ARBs) have established antihypertensive and renoprotective effects, they may be associated with lower rates of TKI-related toxicity. This study evaluated the association between ACEi/ARB use and TKI-associated toxicity.Materials and Methods: We conducted a retrospective observational cohort study using data from the United States TriNetX research network and Penn State Hershey Medical Center (HMC). Patients receiving TKI therapy were stratified according to concurrent ACEi/ARB use. Primary endpoints included kidney function parameters (urine protein, blood urea nitrogen [BUN], and creatinine) and blood pressure measurements. Secondary outcomes included TKI dose discontinuation events. Group comparisons were performed using the Wilcoxon rank-sum test for continuous variables and Fisher exact test for categorical outcomes.

Results

In the combined TriNetX and HMC cohorts, ACEi/ARB use was associated with a statistically significant reduction in documented proteinuria diagnoses (absolute reduction, 19.1%; p=0.036). No significant differences were observed in BUN levels or systolic or diastolic blood pressure. In the HMC cohort, ACEi/ARB use was associated with lower creatinine levels at 4–6 weeks after ACEi/ARB initiation (mean reduction, -0.4 mg/dL; p=0.050) and a 13.7% absolute reduction in TKI discontinuation events. Because of the retrospective observational design and absence of adjustment for baseline confounders, these findings should be interpreted as associative.

Conclusion

ACEi/ARB use was associated with lower rates of proteinuria, possible improvement in creatinine levels, and fewer treatment discontinuation events. These findings suggest that ACEis/ARBs may help reduce selected TKI-related toxicities. Prospective studies are needed to clarify dose-dependent and temporal effects in patients with renal or vascular comorbidities.

Zitieren

APA

Miller, T. J., Zhu, J., Wheelden, M., Maddukuri, A., Elias, M., Trivedi, N., & Joshi, M. (2026). Retrospective Cohort Study Evaluating the Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and Tyrosine Kinase Inhibitor-Associated Toxicity in Advanced Renal Cell Carcinoma. Journal of Urologic Oncology, 24(2), 162-171. https://doi.org/10.22465/juo.265200060003

Vancouver

Miller TJ, Zhu J, Wheelden M, Maddukuri A, Elias M, Trivedi N, et al. Retrospective Cohort Study Evaluating the Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and Tyrosine Kinase Inhibitor-Associated Toxicity in Advanced Renal Cell Carcinoma. Journal of Urologic Oncology. 2026;24(2):162-171. doi:10.22465/juo.265200060003

BibTeX
@article{Miller2026,
  author = {Miller, Theodore Joseph and Zhu, Junjia and Wheelden, Megan and Maddukuri, Ashok and Elias, Michael and Trivedi, Naman and Joshi, Monika},
  title = {Retrospective Cohort Study Evaluating the Association Between Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and Tyrosine Kinase Inhibitor-Associated Toxicity in Advanced Renal Cell Carcinoma},
  journal = {Journal of Urologic Oncology},
  year = {2026},
  volume = {24},
  number = {2},
  pages = {162--171},
  doi = {10.22465/juo.265200060003}
}
Kostenlos starten →